EVerZom
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
EVerZom firmographics
Firmographics- Name
- EVerZom
- Legal name
- EVerZom
- Website
- https://everzom.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
EVerZom industry classification
Industry- Product category
- Exosome Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE)
- akta.pro secondary industry
- Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)
Keywords
Where EVerZom is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
EVerZom business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Proprietary Drug Development: Development of proprietary exosome-based therapeutic products (EVerGel, EViv) targeting inflammatory and regenerative medicine indications. Revenue will be generated through clinical development, regulatory approvals, and commercialization of drug products.
- B2B Contract Manufacturing & Production Services: EVerZom commercializes its exosome production know-how in B2B arrangements to other biotechs and pharmaceutical companies. The company currently sells its production expertise and services to external clients while developing its own pipeline.
- Co-development and Licensing Partnerships: Strategic co-development partnerships with pharmaceutical companies in targeted therapeutic areas (wound healing, liver regeneration, kidney regeneration, oncology). Revenue derived from milestone payments, licensing fees, and potential royalties.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B production services and contract manufacturing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
EVerZom product offering
Product offeringCore offering
EVerZom develops and manufactures exosome-based biotherapies through a proprietary innovation platform covering cell sourcing, exosome generation via turbulent flow bioreactors, exosome engineering (turbuloporation), and formulation including thermoresponsive hydrogels. The company advances proprietary drug candidates (EVerGel for Crohn's fistula/digestive healing, EViv for Acute Chronic Liver Failure) and offers GMP-grade exosome contract manufacturing and co-development services to other biotechs and pharmaceutical companies.
Product overview
EVerZom is a French biotech company founded in 2019 and headquartered in Paris, developing exosome-based biotherapies through its proprietary innovation platform. The company is developing two drug candidates: EVerGel (an exosome-based thermoresponsive hydrogel product for digestive tissue healing, targeting Crohn's disease-associated fistulas and anastomotic healing) and EViv (for acute chronic liver failure). The innovation platform covers the complete technological value chain including mother cell source selection and modification, high-yield exosome generation via turbulent flow bioreactors, exosome engineering through turbuloporation technology, and exosome formulation including thermoresponsive hydrogels. EVerZom is targeting regenerative medicine applications in hepatology, gastroenterology, and dermatology.
Differentiator
Problem solved
Functional benefit
Brands
- EVerGel: Exosome-based therapeutic product delivered via thermoresponsive hydrogel for promoting controlled release and healing at site of interest. Developed for complex perianal fistula associated with Crohn's disease and anastomotic healing.
- EViv
Products and services
- EVerGel Exosome-based therapeutic product delivered via a thermoresponsive hydrogel, designed to promote controlled release and retention at the site of injury. Composed of exosomes produced from human adipose stem cells using EVerZom's proprietary cGMP turbulent flow process, embedded in a hydrogel that is injected in liquid state below 20°C and gels at body temperature. Being developed for complex perianal fistula associated with Crohn's disease (primary indication) and anastomotic healing following colorectal/esophageal cancer surgery.
- EViv Exosome-based drug candidate leveraging exosomes from mesenchymal stem cells, being developed for Acute Chronic Liver Failure (ACLF), a life-threatening medical condition characterized by sudden hepatic decompensation with associated organ failures and high mortality (no approved drug available; 28-day mortality of 23% in ACLF-1 rising to >75% in Grade 3).
- B2B Exosome Contract Manufacturing Services GMP-compatible exosome contract manufacturing service offered to biotech and pharmaceutical companies. Includes exosome generation at scale using EVerZom's turbulent flow bioreactor technology, exosome engineering via turbuloporation (cargo loading), and formulation. Address the industry's key bottleneck in producing clinical-grade exosome quantities at scale.
- Co-Development and Licensing Partnerships Strategic co-development and licensing program offering pharmaceutical partners access to EVerZom's proprietary exosome platform for joint development in specified therapeutic areas. Revenue is generated through milestone payments, licensing fees, and potential royalties. GENFIT collaboration for ACLF (announced November 2025) is an example.
Quantifiable outcome
- 10x more vesicles produced in 1/10th the time compared to conventional MSC methods
- +4 more outcomes
Companies that use EVerZom
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
EVerZom technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
EVerZom partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GENFITcoreGENFIT entered a research collaboration with EVerZom to develop exosome-based regenerative therapy for ACLF (Acute Chronic Liver Failure). The collaboration involves evaluation of EViv, a drug candidate leveraging exosomes from mesenchymal stem cells. An exploratory study is expected to conclude within 18 months, with potential licensing options for GENFIT if successful.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
EVerZom competitors and assessment
Company assessmentDirect peers
- Evox Therapeutics: UK-based clinical-stage biotech developing engineered exosome therapeutics for rare diseases and CNS indications. Closest comparable to EVerZom in platform technology, therapeutic modality (extracellular vesicles), and B2B + proprietary drug development model.
- Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle therapies (notably CAP-1002 for Duchenne muscular dystrophy and cardiac indications). Directly comparable therapeutic modality and regenerative medicine focus.
- ExoCoBio: South Korea-based exosome therapeutics and CDMO company operating both proprietary product development and contract manufacturing services — closely mirroring EVerZom's dual revenue model.
- Codiak BioSciences: Pioneering engineered exosome therapeutics company (referenced as a comparable breakthrough in EVerZom's market context). Closely comparable platform technology and therapeutic approach, though it ceased independent operations in 2023 — illustrating the field's commercial challenges.
Broad incumbents
- TiGenix (Takeda): Acquired by Takeda in 2018, TiGenix developed darvadstrocel, the first approved stem cell therapy for complex perianal Crohn's fistulas — the exact primary indication of EVerZom's EVerGel candidate, making it the most direct competitive reference point.
- Mesoblast: Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and immune-mediated diseases. Comparable broader category player using MSC-derived approaches, including exosomes, for similar therapeutic indications.
- Athersys: Clinical-stage regenerative medicine company developing cell therapies for inflammatory and ischemic conditions. Comparable regenerative medicine peer targeting similar high-unmet-need indications.
Others
- RoosterBio: US-based cell and exosome manufacturing technology provider offering product platforms, services, and media to commercialize MSC-based and EV-based therapies. Comparable as a CDMO competitor for EVerZom's B2B manufacturing business.
- GENFIT: French late-stage biotech focused on hepatology (notably ACLF/NASH), and EVerZom's announced research collaboration partner for EViv. Relevant as both a strategic comparator in hepatology and the most credible validation point for EVerZom's platform.
Emerging players
- Aegle Therapeutics: US-based clinical-stage biotech developing exosome-based therapies derived from mesenchymal stem cells for dermatological and rare diseases. Comparable emerging player in the same exosome therapeutic space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
EVerZom social profiles
Digital presenceEVerZom financial estimates
Financial estimateRevenue estimate
Valuation estimate
EVerZom leadership team
Management profileNumber of profiles
Profiles5 records
EVerZom funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EVerZom M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EVerZom
What does EVerZom do?
EVerZom develops and manufactures exosome-based biotherapies through a proprietary innovation platform covering cell sourcing, exosome generation via turbulent flow bioreactors, exosome engineering (turbuloporation), and formulation including thermoresponsive hydrogels. The company advances proprietary drug candidates (EVerGel for Crohn's fistula/digestive healing, EViv for Acute Chronic Liver Failure) and offers GMP-grade exosome contract manufacturing and co-development services to other biotechs and pharmaceutical companies.
Is EVerZom a public or private company?
EVerZom is a private company. It is classified as venture growth investor backed and is currently operating.
When was EVerZom founded?
EVerZom was founded in 2019. It employs 1 to 10 people.
Where is EVerZom based?
EVerZom is headquartered in Paris, France, in the Europe region.
How does EVerZom make money?
Three revenue lines are on record. Proprietary Drug Development is the primary driver. The others are B2B Contract Manufacturing & Production Services and co-development and Licensing Partnerships.
Who are EVerZom's main competitors?
Direct peers on record are Evox Therapeutics, Capricor Therapeutics, ExoCoBio and Codiak BioSciences. Broad incumbents are TiGenix (Takeda), Mesoblast and Athersys. Others are RoosterBio and GENFIT. Aegle Therapeutics is listed as an emerging player.
Does EVerZom have an API?
No public API is recorded for EVerZom.
What industry is EVerZom in?
EVerZom's product category is Exosome Biotherapeutics. Its primary akta.pro industry code is HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics, with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 325414 and its SIC code is 2836.